Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer

Clinical Oncology

Volumn 21, Issue 6, 2009, Pages 448-450

  Rhiem, K ^a   Wappenschmidt, B ^a   Bosse, K ^a   Koppler H ^b   Tutt, A N ^c   Schmutzler, R K ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Hematology and Oncology Practice   (Germany)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

BRCA1; breast cancer; chemotherapy; cisplatin; metastases

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GEMCITABINE; PROGESTERONE RECEPTOR; SILICON; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BRAIN METASTASIS; BREAST CANCER; BREAST PROSTHESIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ASSOCIATION; HEADACHE; HEARING LOSS; HISTOPATHOLOGY; HODGKIN DISEASE; HOMOLOGOUS RECOMBINATION; HOSPITAL READMISSION; HUMAN; IN VITRO STUDY; LINEAR ACCELERATOR; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT DECISION MAKING; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RADIOSURGERY; VISUAL IMPAIRMENT;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 67649661944     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.01.006     Document Type: Article

References (7)

1. Lakhani S.R., van de Vijver M.J., Jaquemier J., et al. The pathology of familial breast cancer: predictive value or immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
2. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., and Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275 (2007) 23899-23903
3. Husain A., He G., Venkatraman E.S., and Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58 (1998) 1120-1123
4. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller Z., and Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 22 (2003) 1169-1173
5. Meindl A. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97 (2002) 472-480
6. Majdak E.J., Debniak J., Milczek T., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104 5 (2005 Sep 1) 1004-1012
7. Tassone P., Tagliaferri P., Perricelli A., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88 (2003) 1285-1291